Novo and Dayforce Jumps; Apple Headset

On this episode of Stock Movers:
- Novo Nordisk (NVO) shares advanced after the drugmaker's weight-loss drug Wegovy received US approval to treat a serious form of liver disease. The US Food and Drug Administration's decision "could start to help shift the momentum for Novo following a more difficult start to the year," according to Evan David Seigerman, an analyst at BMO Capital Markets.
- Dayforce (DAY) shares are higher on news Thoma Bravo is in talks to acquire human resources management software provider Dayforce Inc., according to people familiar with the matter. The buyout firm is planning to take the Minneapolis-based company private in a deal that could be announced as soon as the coming weeks, the people said.
- Apple (APPL) shares are reacting to news Apple’s Vision Pro headset isn’t selling well for two reasons: its $3,499 price tag and a lack of sufficiently compelling features. That's according to a report from Bloomberg's Mark Gurman. There are other issues — like a limited array of custom applications, the device’s weight and a cumbersome setup process.

See omnystudio.com/listener for privacy information.